<DOC>
	<DOCNO>NCT00620321</DOCNO>
	<brief_summary>The purpose study understand safety profile LY2181308 sodium administer combination idarubicin cytarabine patient relapse refractory AML .</brief_summary>
	<brief_title>A Study LY2181308 Sodium Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patients diagnosis acute myeloid leukemia relapse refractory least 1 prior treatment leukemia , patient chronic myeloid leukemia ( CML ) myeloid blast crisis fail least 1 previous tyrosine kinase inhibitor ( TK1 ) . A baseline bone marrow assessment require less equal 96 hour prior first dose study drug . Must discontinue previous therapy cancer , include chemotherapy , radiotherapy , immunotherapy , cancer relate hormone therapy , investigational therapy least 21 day myelosuppressive agent ( cytarabine , daunorubicin , gemtuzumab ozogamicin ) 14 day nonmyelosuppressive agent prior receive study drug , recover acute effect therapy ( neurotoxicity , diarrhea , mucositis ) except residual myelosuppression alopecia . Hydroxyurea permit control peripheral blast cell count , must stop least 24 hour study drug administration . administration . Must adequate organ function . Females must negative pregnancy test . Male female patient must agree use reliable method birth control 6 month follow last dose study drug . Patients must least 18 year old . Have receive treatment within last 30 day drug receive regulatory approval indication within 14 21 day initial dose study drug nonmyelosuppressive myelosuppressive agent , respectively . Patients acute promyelocytic leukemia ( APML ) . Major surgery within 4 week study enrollment . Patients serious preexist medical condition ( discretion investigator ) . Because known cardiac toxicity anthra cyclines , patient preexist ejection fraction ( EF ) less equal 45 % participate study . No patient exceed maximum exposure anthracycline dos ( example , idarubicin great 120mg/m2 ) . Patients second malignancy could affect interpretation result . Patients leukemic involvement CNS spinal fluid cytology image . Patients know coagulopathy bleeding disorder , leukemia relate thrombocytopenia . Patients severe life threaten bleed refractory platelet transfusion also exclude . Concomitant anticoagulant therapy ( exception heparinized saline maintain patency central venous catheter ) . Women pregnant breast feeding . Patients know hypersensitivity oligonucleotides , idarubicin , and/or cytarabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>